HUMA Aug 2024 2.500 call
| Previous close | 2.5000 |
| Open | 2.9800 |
| Bid | 1.0500 |
| Ask | 3.5000 |
| Strike | 2.50 |
| Expiry date | 2024-08-16 |
| Day's range | 2.9000 - 2.9800 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
Simply Wall St.While institutions own 20% of Humacyte, Inc. (NASDAQ:HUMA), individual investors are its largest shareholders with 50% ownership
Key Insights Humacyte's significant individual investors ownership suggests that the key decisions are influenced by...
GlobeNewswireHumacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
– Third RMAT designation by FDA for ATEV – – RMAT will expedite development of ATEV in PAD – DURHAM, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, has been granted the U.S. Food and Drug Administration’s (FDA’s) Regenerative Medicine Advanced Therapy (RMAT) designation for patients with advanced peripheral artery disease (PAD). This RMAT de
- GlobeNewswire
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived islets observed to restore normal blood glucose in diabetic mice – – Non-human primate models of BVP implantation showed islet survival and continued insulin production – DURHAM, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human
